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Introduction
Activated protein C (APC) is an anticoagulant, resem-
bling serine enzyme, which is generated from protein
C (PC) under the effect of the thrombin/thrombomod-
ulin (TM) complex, with the involvement of protein S
(PS) as a co-factor. Researchers frequently refer to the
protein C system or protein C anticoagulant pathway.
A further component of the protein C anticoagulant
pathway is the endothelial protein C receptor (EPCR)
that augments protein C activation and potentiates the
activity of APC. Moreover, the protein C system con-
tains protein C inhibitor (PCI).
Proteins C and S occur in the plasma. These vita-
min K-dependent proteins are synthesized in the liver.
TM is synthesized within endothelial cells and
expressed on endothelial surface (cellular TM) or
found outside the cells as soluble TM (sTM). TM is a
thrombin receptor and forms TM/thrombin complexes,
which convert non-active protein C (zymogen) into its
highly active form (APC).
It is believed that APC is the most important vaso-
protective protein due to its anti-thrombotic and anti-
inflammatory as well as anti-apoptotic properties. In
the course of spectacular interactions taking place in
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Abstract: Activated protein C (APC) is an important anticoagulant which plays a role in pathophysiology of pregnancy, e.g.
in maintenance of the uteroplacental circulation and developement of the fetus as well as in pathogenesis of preeclampsia.
The study objective was to compare the levels of the respective components of the protein C system (protein C, PC; protein
S, PS; thrombomodulin, TM) as well as thrombin activatable fibrinolysis inhibitor – TAFI in mother's blood, cord blood and
amniotic fluid. The study group consisted of 136 healthy parturients at term, divided into subgroups of 30-35. The immu-
noenzymatic method (ELISA) was used to measure the antigens of the components studied. The concentrations of PC and
PS antigens were the highest in the mother's blood plasma (135.11±1.05% and 92.0±13.24%, respectively), lower in cord
blood plasma (57.60±10.32% and 33.19±4.96%, respectively) and the lowest in amniotic fluid (6.75±3.50% and
2.40±1.64%, respectively); the differences between the levels of that of mother, fetus and amniotic fluid were statistically
significant (p≤0.0001). The TM and TAFI antigen concentrations were the highest in cord blood plasma (11.35±3.71 ng/ml
and 91.50 (median; range: 71.76-160.77) ng/ml, respectively) and lower in maternal plasma (4.51±0.71 ng/ml and 55.46 –
median; range: 39.77-68.54 ng/ml, respectively); the differences between the levels of that of cord blood plasma and mater-
nal plasma were statistically significant (p≤0.0001). Of the three protein C system components, PC and PS occur in rela-
tively high concentrations in maternal blood, being lower in fetal blood and the lowest in amniotic fluid. On the other hand,
as an exception, the concentrations of TM and TAFI are the highest in fetus blood. 
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the protein C system, thrombin changes its procoagu-
lant activity into anticoagulant activity, and activation
of the proteinase-activated receptor 1 (PAR-1) occurs,
being a link between coagulation and inflammation
responses. APC degrades clotting factors Va and VIIIa
in tenase and prothrombinase complexes, in this way
attenuating thrombin generation, and in addition it
transforms pro-TAFI into TAFI (Thrombin Activatable
Fibrinolysis Inhibitor) [1,2] (Fig. 1).  
Due to high TM level in the placenta and
myometrium [3] as well as to the placental concen-
tration of EPCR receptors, APC is probably the major
anticoagulant of the uteroplacental circulation poten-
tiating the antithrombogenic effect of APC [4,5].
Also in general circulation, APC plays a role of an
important anticoagulant – the second after antithrom-
bin (AT) or even the first one, making up the
antithrombogenic activity of the vascular wall. In a
pregnant woman, a decrease in vascular antithrombo-
genic activity (a drop in AT and APC) may lead to
preeclampsia (assumption of a preeclampsia hypoth-
esis [6]). According to diabetologists, the pathogene-
sis of diabetic nephropathy indicates a pathogenetic
relationship with reduced APC activity in the kidney
(a direct effect of TM deficiency in glomerular
endothelium) [7].
Although relatively much has been known about
APC function in the blood of pregnant women, the
knowledge of APC in fetal blood and amniotic fluid is
still preliminary, perhaps due to the fact that the data
concerning the concentrations of this system compo-
nents are still incomplete. 
The objective of the current study was to compare
the levels of proteins C and S and thrombomodulin
(TM) in three fluid compartments of the mother and
the fetus, i.e. in maternal blood, in fetal blood (cord
blood) and amniotic fluid, as well as TAFI concentra-
tions in these compartments. 
Material and methods
Patients. The material sample included 136 parturients at term,
22.1±3.2 years of age, 88 primiparas and 48 multiparas, with a sin-
gleton and uneventful pregnancy (complicated cases were exclud-
ed from the analysis). To study the components of the protein C
system: protein C, protein S, thrombomodulin and TAFI the
women were divided into groups of 30-35. Each group had a con-
trol counterpart (15-20 non-pregnant healthy women, on day 18-26
of menstrual cycle, age-matched with the study group). 
Sampling of mother's blood, cord blood and amniotic fluid.
The materials were collected immediately after delivery of the
fetus, before placenta expulsion and before clumping of the umbil-
ical cord. 
Maternal venous blood was obtained by puncturing the antecu-
bital vein without occlusion. Sodium citrate (3.2%) was used as
anticoagulant (one part of anticoagulant to nine parts of blood).
Control blood was obtained in a similar way from the control
group.Cord blood was obtained by puncturing the umbilical vein.
Sodium citrate in the same concentration and the
anticoagulant/blood ratio as in the mother were used. Amniotic
fluid was collected from the waters that were flowing out from the
uterus after fetus delivery (fluid contaminated with blood was
excluded from analysis). The syringe used to collect the fluid con-
tained the same amount of sodium citrate as for blood collection.
All the samples (mother's blood, cord blood, amniotic fluid, con-
trol blood) were placed into ice water, transported to the laborato-
ry and then centrifuged (2500 × g for 20 min at +4°C); 200 µl por-
tions of plasma and the supernatant of amniotic fluid were trans-
ferred into plastic test-tubes, which were tightly closed and stored
for 2-3 weeks at -70°C.
Laboratory measurements. The concentrations of protein C
(PC), protein S (PS) and soluble thrombomodulin (sTM) were
determined by the immunoenzymatic method (ELISA), using
respectively ASSERACHROME Protein C, ASSERACHROME
Protein S from Diagnostica Stago Roche, and IMUBIND Throm-
bomodulin ELISA Kit of American Diagnostica. The reference val-
ues for adults (plasma) were: protein C – 70-140%, protein S – 70-
140%, thrombomodulin in the plasma of non-pregnant women
from 2.73 ng/ml (21-30 years) to 4.79 ng/ml (61-70 years). Throm-
bin activatable fibrinolysis inhibitor (TAFI) antigen was measured
also by ELISA, using IMUBIND TAFI a/ai Antigen ELISA kit
from American Diagnostica Inc., which measures TAFIa and
TAFIai (inactive TAFIa). The lower limit of TAFI antigen detec-
tion recommended by the manufacturer is 10 ng/ml. In our labora-
tory, the inter-assay and intra-assay coefficients of variability were
lower then 10%. The level of protein (total protein) was measured
by BCA method.
Ethical issues. All patients were informed about the research and
they gave informed consent for sampling of the material.
Statistical analysis. The results are presented as mean values with-
in standard deviation for normally distributed variables (PC, PS
and TM), and as median and range for those different from nor-
mally distributed variables (TAFI). Statistical analysis was per-
formed using two tests: (i) the ANOVA Friedman's test for the
comparison of paired data (mother' plasma vs. cord blood, plasma
or amniotic fluid; (ii) non- parametric Mann-Whitney and Wilcox-
on tests for evaluation of unpaired data (pregnant vs. non-preg-
nant). The significance limit was chosen at p value ≤0.05.
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Fig. 1. Protein C pathway: 1) generation of activated protein C
(APC) under the effect of the trombin/thrombomodulin complex,
2) activity of APC: (a) inactivation of Va and VIII a factors, (b)
generation of TAFI (thrombin activatable fibrinolysis inhibitor).
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The concentration of protein C antigen in mother's
plasma was 135.11±1.05%, whereas in cord plasma
57.60±10.32%, thus it was lower by over a half
(42.67%) in the fetus as compared to the mother
(p≤0.0001). In the amniotic fluid, the level was
6.75±3.50%, i.e. only a fraction of the values found in
the mother and fetus (4.99% and 11.72%, respectively)
(p≤0.0001). In control (non-pregnant women), the
level was 94.78±12.46% ( Fig. 2).
Protein S
The level of total protein S in mother's plasma was
92.49±13.24%, whereas in cord plasma 33.19±4.96%,
thus being almost threefold lower (35.88%) in the
fetus than in the mother (p≤0.0001). In amniotic fluid,
it was 2.40±1.64%, i.e. only a fraction of the concen-
trations detected in the mother and fetus (2.59% and
7.23%, respectively). In control (non-pregnant
women), the level was 93.47±8.36% (Fig. 3).
Thrombomodulin
The level of TM antigen in mother's plasma was
4.51±0.71 ng/ml and in cord plasma 11.35±3.71
ng/ml, i.e. it was almost three times higher in the
fetus than in the mother (251.66% of the value found
in the mother) (p≤0.0001). In amniotic fluid, the level
of TM was 2.71±1.21 ng/ml, which accounted for
60.08% of the maternal concentration value
(p≤0.018). In control (non-pregnant women), it was
3.86±0.92 ng/ml (Fig. 4).
TAFI
The level of TAFI antigen was 55.46 (39.77-68.54)
ng/ml in the mother's plasma and 91.50 (71.76-160.77)
ng/ml in cord plasma, thus being nearly twice as high
in the fetus than in the mother (164.98% of the moth-
er's level) (p≤0.0001). However, in amniotic fluid it
was similar to that in the mother's plasma (p≥0.3389).
In control (non-pregnant women), the concentration
was 72.55 (67.50-76.69) ng/ml (Fig. 5). 
Total protein
Total protein in mother's plasma was 83.27±11.54
mg/ml, in cord blood plasma was 85.82±21.87 mg/ml,
and 2.96±1.05 mg/ml in amniotic fluid.
Discussion
APC, an anticoagulant with the activity of the serine
enzyme is generated in the dynamic system called the
protein C system or protein C anticoagulant pathway.
The major components of this system are PC, PS and
TM, in which PC undergoes conversion into APC under
the influence of the thrombin/thrombomodulin complex.
We knew about the presence of PC, PS and TM as
well as TAFI – one of the APC activity products – in
fluid compartments of the mother and fetus from earli-
er investigations performed by our team [9,10], or
from studies carried out by other researchers [11-14].
In the current study, we examined the levels of the four
above mentioned antigens simultaneously in all the
three compartments, which allowed making compar-
isons. Our results are either similar [11] or compatible
with the studies mentioned above. However, altogeth-
er the studies should be treated as preliminary. 
Fig. 2. The concentration of protein C antigen in moternal blood
plasma, cord blood plasma and in amniotic fluid.
Fig. 3. The level of total protein S in maternal plasma, cord blood
plasma and in amniotic fluid.
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It is known that the fluid compartments of the
mother and the fetus are functionally different and at
the same time related, which shows the anatomical and
functional interrelationship of the fetus and the moth-
er, referred to as the fetal-maternal unity. 
The concentration of proteins is one of the distinc-
tive features of these compartments. The so called pla-
cental barrier hinders protein permeation through the
placenta and fetal membranes both from the mother to
the fetus (permeation of maternal IgM antibodies to
the fetus is a known exception) and in the opposite
direction. Because of this, the levels of the respective
proteins in maternal and fetal blood provide evidence
of their synthesis in these compartments. Our findings
do not deny the previously accepted rules that: (i) the
levels of total protein and coagulation proteins are
higher in maternal blood than in fetal blood (rule 1);
(ii) the levels of total protein and coagulation proteins
in amniotic fluid are lower than in maternal blood and
in fetal blood (rule 2). However, we have found a few
exceptions to these, noting that the level of TM is more
than twofold higher in fetal than in maternal blood and
that the level of TAFI is nearly twice as high. These
two observations require a comment.  
Two other teams examined the level of TM in fetal
blood [13,14]. According to Menashi et al. [13],
between week 23 and week 26 of gestation the level of
TM reached a peak of approximately 165 ng/ml, being
108 ng/ml of plasma at term delivery; according to
Orbe et al. [14], TM concentration at term delivery
was 53.6±16.4 ng/ml. We found this concentration to
be 11.35±3.71 ng/ml at term delivery, and twofold
higher than in mother's blood. The results appear to
vary, which is undoubtedly due to the application of
different reagents and methods of measurement. Nev-
ertheless, these investigations provide evidence of a
relatively high TM level in the fetus. Worthy of note is
also the fact that the cited authors made no comparison
with adult plasma, which has been a research require-
ment since 1991 [8] .
The role of TM in the fetus can be diverse: (i) TM
can up- or down-regulate APC production depending
on the levels of TAFI and active fraction of PS, as
reported in literature [15-18]; (ii) the premises of the
studies conducted on the animal model (mice)
[19,20] suggest that TM exerts not only a hemostatic
effect but also has an essential impact on fetal devel-
opment (ontogenetic effect); (iii) it can be assumed
that TAFI is produced more intensively in fetal than
in maternal blood and is associated with APC activi-
ty or the factors/products of the protein C system.
Undoubtedly, further studies are necessary to eluci-
date the problem. 
Conclusions
Protein C (PC), protein S (PS) and thrombomodulin
(TM) – the proteins of the protein C anticoagulant
pathway – as well as thrombin activatable fibrinoly-
sis inhibitor (TAFI) – the product of activated pro-
tein C (APC) – are present in mother's blood, cord
blood and in amniotic fluid. There are exceptions to
the rule according to which the level of procoagu-
lants and anticoagulants in fetal blood is lower than
in mother's blood: it has turned out that the levels of
TM and TAFI are higher in fetal than in maternal
blood. According to literature survey, certain compo-
nents of the protein C system (TM) may have an
effect on the development of the fetus (ontogenetic
effect).
Fig. 4. The level of thrombomodulin (TM) antigen in maternal
plasma, cord blood plasma and in amniotic fluid.
Fig. 5. The level of thrombin activatable fibrinolysis inhibitor
(TAFI) in maternal plasma, cord blood plasma and in amniotic
fluid
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